Table of Contents
Volume 5 | Issue 2
Publication Date: September 2004
Abstract
No Access
Pay-Per View
Full Text
Add to Cart
Meeting Highlights | ||
 74-80 |
From: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana Nancy Price, G. Kesava Reddy, Susan Peck, Vinay K. Jain |
|
Research in Brief | ||
81-83 |
Rituximab Improves Rate and Duration of Chemotherapy-Induced Remissions in Indolent and Aggressive Non-Hodgkin’s Lymphoma Angelia D. Gibson, Vinay K. Jain |
|
Original Contribution | ||
84-88 |
The Impact of Conventional and High-Dose Therapy for Lymphoma on Fertility Andrew Grigg |
|
Comprehensive Review | ||
89-97 |
Pathology of Primary Cutaneous B-Cell Lymphomas: Diagnosis and Classification Eric D. Hsi |
|
Original Contributions | ||
98-101 |
Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma Leo I. Gordon, Thomas Witzig, Arturo Molina, Myron Czuczman, Christos Emmanouilides, Robin Joyce, Katie Vo, Charles Theuer, Brad Pohlman, Nancy Bartlett, Greg Wiseman, Mohamed Darif, Christine White |
|
102-109 |
Progress in the Prognosis of Adult Hodgkin’s Lymphoma in the Past 35 Years Through Clinical Trials in Argentina: A GATLA Experience Santiago Pavlovsky, Francisco Lastiri |
|
110-115 |
Results of a Phase II Multicenter Trial of Single-Agent Gemcitabine in Patients with Relapsed or Chemotherapy-Refractory Hodgkin’s Lymphoma Hemachandra Venkatesh, Nicholas Di Bella, Thomas P. Flynn, Mark J. Vellek, Kristi A. Boehm, Lina Asmar |
|
116-122 |
Dose-Intense Cyclophosphamide and Etoposide for Patients with Refractory or High-Risk Non-Hodgkin’s Lymphoma Jeffrey Talbot, Valerie K. Ibom, David A. Rizzieri, Robert Barrier, Donna Niedzwieki, Carlos M. DeCastro, Joseph O. Moore, Patrick Buckley, Rhonda Laney, Diane Stevenson, Heather Brumbaugh, Jon P. Gockerman |
|
Brief Communication | ||
123-126 |
Mutational Status of IgVH Genes Consistent with Antigen-Driven Selection but Not Percent of Mutations Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia Massimo Degan, Maurizio Rupolo, Michele Dal Bo, Anna Stefanon, Riccardo Bomben, Antonella Zucchetto, Enrica Canton, Massimiliano Berretta, Paola Nanni, Agostino Steffan, Pier Ferruccio Ballerini, Daniela Damiani, Carlo Pucillo, Vincenza Attadia, Alfonso Colombatti, Valter Gattei |
|
Letter to the Editor | ||
127 |
Can [18F]FDG Positron Emission Tomography Replace Bone Marrow Biopsy in Staging of Malignant Lymphoma? Ralph Naumann, Bettina Beuthien-Baumann |
|
Commentary | ||
128-129 |
Non-Hodgkin’s Lymphoma in the Microarray Era Izidore S. Lossos, Daniel Morgensztern |
|
Current Trial | ||
130-134 |
A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients with Relapsed or Refractory Multiple Myeloma James R. Berenson, Regina A. Swift, Delina Ferretti, Matthew B. Purner |
|
